Adamas Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Adamas Pharma (ADMS) Tops Q1 EPS by 15c
May 10, 2021 4:30 PM EDTAdamas Pharma (NASDAQ: ADMS) reported Q1 EPS of ($0.36), $0.15 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $19.3 million versus the consensus estimate of $20.02 million.
As of March 31, 2021, Adamas had $127.4 million of cash, cash equivalents and available-for-sale securities, compared to $83.4... More
